Ardelyx announces positive Stage 2b outcomes for tenapanor in IBS-C patients Ardelyx.

Ardelyx announces positive Stage 2b outcomes for tenapanor in IBS-C patients Ardelyx, Inc suhagra here . , a clinical-stage biopharmaceutical company focused on cardio-renal, metabolic and gastrointestinal diseases, today announced excellent results from its 371 patient Phase 2b scientific trial evaluating tenapanor in individuals with constipation-predominant irritable bowel syndrome . Results from this study demonstrated statistically significant and clinically meaningful improvement in IBS-C symptoms for tenapanor-treated patients in comparison to patients receiving placebo. At the 50 mg dosage, the study met its main efficacy endpoint of a rise in the complete spontaneous bowel movement responder rate.